Psychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui, Emma Hapke Harm Reduction Journal, 2019. Doi : 10.1186/s12954-019-0308-4 Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the present study, [...]
Lire la suiteAn Overview of Galenic Preparation Methods for Medicinal Cannabis Luigi Romano and Arno Hazekamp Current Bioactive Compounds, 2018, 14, DOI: 10.2174/1573407214666180612080412 Abstract : In recent years, the Cannabis plant (Cannabis sativa L.) has been rediscovered as a source of new medicines around the world. Despite the fact that a number of registered medicines have been developed on the basis of purified cannabis components, there is a rapid increasing acceptance and use of cannabis in its herbal form. Licensed producers of high quality cannabis plants now operate in various countries including The Netherlands, Canada, Israel, and Australia, and in many US states. The legal availability of [...]
Lire la suiteMedical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteToujours plus avec la chimie psychédélique par Thibault Henneton Manière de Voir (Le Monde Diplomatique), 2019, 163, Fruits d’une inventivité chimique sans limites, les nouveaux produits de synthèse (NPS) se sont multipliés ces dix dernières années, notamment dans les milieux festifs alternatifs. Moins chers que la cocaïne, ils restent difficiles à cerner tant pour les autorités que pour les usagers, incapables d’en connaître à l’avance les effets véritables, dont certains mènent aux hôpitaux, désarmés pour les traiter. Akatre ///// « Djeff », 2018 Placés récemment sous les projecteurs, les nouveaux produits de synthèse (NPS) inonderaient le marché des stupéfiants. Dans son dernier rapport annuel, l’Observatoire français des [...]
Lire la suiteThe fourfold discovery of Mescaline (1896–1919) Ivo Gurschler Chemical Monthly, 2019, 150, 941–947 © Springer-Verlag GmbH Austria, part of Springer Nature 2019 https://doi.org/10.1007/s00706-019-02444-0 Abstract This is an historical account of the pharmacological, chemical, and anthropological research concerning the molecular makeup of the peyote cactus (Lophophora williamsii) that laid the ground for Ernst Spaeth’s structural elucidation of mescaline as 3,4,5-trimethoxyphenethylamine. Keywords : History of science · Psychedelic studies · Organic chemistry · Alkaloids · Mescaline · Drugs Introduction The exploration of the constituents of the peyote cactus and its effects upon the human psyche was an interdisciplinary undertaking that defied national borders. The material way to the heart of the [...]
Lire la suiteAlessandro Stella Directeur de recherche CNRS Equipe(s) : GEI Laboratoire(s) de rattachement : CRH Coordonnées professionnelles EHESS-CRH GEI (Bureau A 04-11) 54, boulevard Raspail 75006 Paris alessandro.stella (a) wanadoo.fr 01 49 54 24 42 http://gei.ehess.fr/index.php?942 Diplômes 1987 : Diplôme de l’EHESS, sous la direction de Mme Christiane Klapisch-Zuber : « Sur les traces laissées par les Ciompi en révolte : les hommes, les lieux, le travail », rapporteur M. Jacques Le Goff. Prix du meilleur diplôme de l’EHESS. 1992 : Doctorat de l’EHESS, sous la direction de Mme Christiane Klapisch-Zuber : « Un tableau florentin du Trecento. Fiscalité, topographie et société dans la deuxième moitié du XIVe siècle ». Mention : « Très honorable ». 2007 : Habilitation à Diriger des Recherches, Université [...]
Lire la suiteLe microdosage de substances psychédéliques : bref historique et nouveaux axes de recherche Vittorio Biancardi Revue CIRCE, 2019, 11, 25pp Résumé Le micro-dosage est un phénomène social de plus en plus répandu parmi la communauté des consommateurs et consommatrices des substances dites psychédéliques. Il consiste une consommation d’un dixième de la dose typique de substance (principalement LSD ou Psilocybine) de façon fréquente, deux ou trois fois par semaine, pour améliorer les capacités cognitives ou comme auto-thérapie. L’analyse de ce phénomène est actuellement très fragmentaire et inconsistante, tant du point de vue des sciences humaines que du point de vue des sciences dites «dures». L’objectif [...]
Lire la suiteChronic, Intermittent Microdoses of the Psychedelic N,N‑Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents Lindsay P. Cameron, Charlie J. Benson, Brian C. DeFelice, Oliver Fiehn, and David E. Olson ACS Chemical Neurosciences, 2019 DOI: 10.1021/acschemneuro.8b00692 ABSTRACT : Drugs capable of ameliorating symptoms of depression and anxiety while also improving cognitive function and sociability are highly desirable. Anecdotal reports have suggested that serotonergic psychedelics administered in low doses on a chronic, intermittent schedule, so-called “microdosing”, might produce beneficial effects on mood, anxiety, cognition, and social interaction. Here, we test this hypothesis by subjecting male and female Sprague Dawley rats to behavioral testing following the [...]
Lire la suiteMotives and Side-Effects of Microdosing With Psychedelics Among Users Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers International Journal of Neuropsychopharmacology, 2019, 1–9 doi:10.1093/ijnp/pyz029 Abstract Background : Microdosing with psychedelics has gained considerable media attention where it is portrayed as a performance enhancer, especially popular on the work floor. While reports are in general positive, scientific evidence about potential negative effects is lacking aside from the prevalence and motives for use. The present study addressed this gap by surveying psychedelic users about their experience with microdosing including their dosing schedule, motivation, and potential experienced negative effects. Methods : An [...]
Lire la suiteMicrodosing psychedelics: More questions than answers? An overview and suggestions for future research Kim P.C. Kuypers, Livia Ng, David Erritzoe, Gitte M. Knudsen, Charles D. Nichols, David E. Nichols, Luca Pani, Anaïs Soula and David Nutt Journal of Psychopharmacology, 2019, 1-10. Doi: 10.1177/0269881119857204 Abstract Background : In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cognitive processes such as concentration. However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing [...]
Lire la suite